Clinical trials: Blood Plasma Therapy
Light-Chain Amyloidosis
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated…
- Trial name
- NCT01318902
- Testing
- Ixazomib, Dexamethasone
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
AL Amyloidosis
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy.
- Trial name
- NCT04115956
- Testing
- Melphalan-Flufenamide (Melflufen), Dexamethasone
- Where
- 9 sites in United States, Czechia and 7 more
- Volunteers
- 6 people
- Sponsor
- Oncopeptides AB
Multiple Myeloma
Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
The primary objective is to compare the time to progression (TTP) of three daily doses of thalidomide (100, 200 and 400 mg) with high-dose dexamethasone in relapsed refractory multiple myeloma (MM) patients and to subsequently…
- Trial name
- OPTIMUM (NCT00452569)
- Testing
- Thalidomide, Dexamethasone
- Where
- 86 sites in Bulgaria, Croatia and 13 more
- Volunteers
- 499 people
- Sponsor
- Celgene
Multiple Myeloma
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
The purpose of this study is to assess the 2-year progression-free survival rate.
- Trial name
- NCT02474563
- Testing
- Bortezomib, Melphalan, Prednisone
- Where
- 18 sites in South Korea
- Volunteers
- 171 people
- Sponsor
- Janssen Korea, Ltd., Korea
Multiple Myeloma
Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
The primary objectives of the study are to evaluate the safety profile and the anti-tumor activity of 2 dose levels of natalizumab in participants with relapsed or refractory multiple myeloma.
- Trial name
- NCT00675428
- Testing
- BG00002 (natalizumab)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Biogen
Multiple Myeloma
A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance
A prospective, multicentre, post-authorisation observational study. The objective of this study is assess the response of renal function in clinical practice to anti-multiple myeloma therapy in patients with relapsed MM and CrCl…
- Trial name
- MIR50 (NCT02849444)
- Testing
- Anti-myeloma treatment at physician discretion
- Where
- 40 sites in Spain
- Volunteers
- 326 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur.
- Trial name
- iinnovate-1 (NCT03215030)
- Testing
- Modakafusp alfa, Dexamethasone
- Where
- 94 sites in United States, Canada and 14 more
- Volunteers
- 272 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
HIV Infections, Lymphopenia
Safety Study of IL-7 in HIV-infected Patients (Inspire)
This study will evaluate the safety of a new experimental drug, IL-7, in people with HIV infection. Animal studies have shown that IL-7 can improve the function and number of infection-fighting cells called T lymphocytes, or T…
- Trial name
- NCT00477321
- Testing
- CYT 107
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 30 people
- Sponsor
- Cytheris SA
Primary Immune Thrombocytopenia
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
The study will involve patients with chronic immune thrombocytopenia. This disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons.
- Trial name
- NCT05422365
- Testing
- Intravenous immunoglobulin (IVIG), 10% solution for infusion
- Where
- 12 sites in Ukraine
- Volunteers
- 32 people
- Sponsor
- Biopharma Plasma LLC
Parkinson Disease
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD…
- Trial name
- NCT00560508
- Testing
- Pramipexole Immediate Release, Pramipexole Extended Release
- Where
- 19 sites in Japan
- Volunteers
- 112 people
- Sponsor
- Boehringer Ingelheim
Peri Implant Mucositis, Peri Implantitis
Study on the Treatment of Dental Implants Using the AmbiJet System for Peri-implantitis and Peri-implant Mucositis
Inflammation of the tissue surrounding a dental implant (peri-implantitis or peri-implant mucositis) can lead to implant loss in advanced stages.
- Trial name
- AmbiJet-FIH (NCT07722715)
- Testing
- AmbiJet cold plasma system, Standard Mechanical Debridement (S3 Guideline)
- Where
- Ukraine
- Volunteers
- 26 people
- Sponsor
- Freiburger Medizintechnik GmbH
B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma
Study of MLN8237 in Participants With Advanced Hematological Malignancies
This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.
- Conditions
- B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma
- Trial name
- NCT00697346
- Testing
- Alisertib
- Where
- 10 sites in United States
- Volunteers
- 58 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Redirected Auto T Cells for Advanced Myeloma
The purpose of this study is to 1) evaluate the safety and tolerability of autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR in HLA-A2+ subjects and 2) measure the incidence of GVHD…
- Trial name
- NCT01352286
- Testing
- Autologous Genetically modified T cells
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with…
- Trial name
- NCT02605356
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Bortezomib, Dexamethasone
- Where
- 58 sites in United States, Australia and 9 more
- Sponsor
- Bayer
Multiple Myeloma
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of NOX A12 alone and in combination with a background therapy of bortezomib and dexamethasone (VD) chemotherapy in previously treated patients with multiple myeloma…
- Trial name
- NCT01521533
- Testing
- NOX-A12
- Where
- 10 sites in Austria, France and 2 more
- Volunteers
- 28 people
- Sponsor
- TME Pharma AG
Multiple Myeloma
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
- Trial name
- iMMagine-1 (NCT05396885)
- Testing
- anitocabtagene-autoleucel
- Where
- 18 sites in United States
- Volunteers
- 136 people
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory Multiple Myeloma
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
The clinical trial was designed as a single-arm, open-label clinical study, with the main purpose of exploring the safety, pharmacokinetics, and best recommended dose (RP2D) of the UTAA17 injection in the treatment of relapsed or…
- Trial name
- NCT06279026
- Testing
- UTAA17 Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Relapsed or Refractory Multiple Myeloma
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the…
- Trial name
- NCT07681596
- Testing
- AZD4045, Daratumumab, Aldesleukin
- Where
- 12 sites in United States, Australia
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Breast Cancer, Lung Cancer
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
The Carevive registry collects patient characteristics, patient symptoms, and treatment experience data from patients receiving cancer treatment for breast, lung, GI or multiple myeloma.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Multiple Myeloma
- Trial name
- NCT05587972
- Testing
- survey
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Carevive Systems, Inc.
Multiple Myeloma, Peripheral Neuropathy
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients
This is a prospective study investigating the relationship between vitamin D and peripheral neuropathy (PN) among multiple myeloma (MM) patients treated with either bortezomib or thalidomide.
- Trial name
- NCT01697839
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Oncotherapeutics